Coronary disease & ACSSecondary analysis
The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk
- Secondary analysis of the LoDoCo2 randomised trial
- biomarker subpopulation
Authors' conclusion
In patients with CCS, colchicine reduces cardiovascular disease risk in those with and without elevated Lp(a) but absolute benefits appeared higher in those with Lp(a) ≥ 125 nmol/L. Patients with higher levels of OxPL-apoB experienced greater benefit of colchicine, suggesting that colchicine may be more effective in subjects with heightened oxidation-driven inflammation.
Study context
- Population
- Patients with chronic coronary syndrome (CCS) in the LoDoCo2 biomarker populationbiomarker population
- Participants
- 1,777 patients
- Comparison
- Colchicine vs placebo, by Lp and OxPL levels
- Primary endpoint
- MI, ischaemic stroke or ischaemia-driven revascularization, by biomarker levels
Primary result
As reported in the abstract
Consistent risk reduction by colchicine with Lp(a) <125 and ≥125 nmol/L and highest vs lowest OxPL-apo(a) tertile
Pinteraction = 0.92 and 0.66
Absolute risk reduction, Lp(a) ≥125 vs <125 nmol/L
4.4% vs. 2.4%
Treatment interaction, highest vs lowest OxPL-apoB tertile
Pinteraction = 0.04
Further findings
Lp(a), OxPL-apo(a) and OxPL-apoB levels
- Similar between colchicine and placebo
Original publication
Summarised from the published abstract; every number is checked against it